Deng Y, Jing Y, Campbell AE, Gravenstein S: Age-related impaired type 1 T cell responses to influenza: reduced activation ex vivo, decreased expansion in CTL culture in vitro, and blunted response to influenza vaccination in vivo in the elderly. J Immunol. 2004, 172: 3437-3446.
Article
CAS
PubMed
Google Scholar
Goodwin K, Viboud C, Simonsen L: Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine. 2006, 24: 1159-1169.
Article
CAS
PubMed
Google Scholar
McElhaney JE: Prevention of infectious diseases in older adults through immunization: the challenge of the senescent immune response. Expert Rev Vaccines. 2009, 8: 593-606.
Article
PubMed
Google Scholar
McElhaney JE, Dutz JP: Better influenza vaccines for older people: what will it take?. J Infect Dis. 2008, 198: 632-634.
Article
PubMed
Google Scholar
Weinberger B, Herndler-Brandstetter D, Schwanninger A, Weiskopf D, Grubeck-Loebenstein B: Biology of immune responses to vaccines in elderly persons. Clin Infect Dis. 2008, 46: 1078-1084.
Article
PubMed
Google Scholar
Lefebvre JS, Haynes L: Vaccine strategies to enhance immune responses in the aged. Curr Opin Immunol. 2013, 25: 523-528.
Article
CAS
PubMed
PubMed Central
Google Scholar
Falsey AR, Treanor JJ, Tornieporth N, Capellan J, Gorse GJ: Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis. 2009, 200: 172-180.
Article
CAS
PubMed
Google Scholar
Keitel WA, Atmar RL, Cate TR, Petersen NJ, Greenberg SB, Ruben F, Couch RB: Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch Intern Med. 2006, 166: 1121-1127.
Article
PubMed
Google Scholar
Harandi AM, Davies G, Olesen OF: Vaccine adjuvants: scientific challenges and strategic initiatives. Expert Rev Vaccines. 2009, 8: 293-298.
Article
CAS
PubMed
Google Scholar
Clark TW, Pareek M, Hoschler K, Dillon H, Nicholson KG, Groth N, Stephenson I: Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med. 2009, 361: 2424-2435.
Article
CAS
PubMed
Google Scholar
Leroux-Roels I, Borkowski A, Vanwolleghem T, Dramé M, Clement F, Hons E, Devaster JM, Leroux-Roels G: Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet. 2007, 370: 580-589.
Article
CAS
PubMed
Google Scholar
Levie K, Leroux-Roels I, Hoppenbrouwers K, Kervyn AD, Vandermeulen C, Forgus S, Leroux-Roels G, Pichon S, Kusters I: An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults. J Infect Dis. 2008, 198: 642-649.
Article
PubMed
Google Scholar
O’Hagan DT: MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert Rev Vaccines. 2007, 6: 699-710.
Article
PubMed
Google Scholar
Roman F, Clément F, Dewé W, Walravens K, Maes C, Willekens J, De Boever F, Hanon E, Leroux-Roels G: Effect on cellular and humoral immune responses of the AS03 adjuvant system in an A/H1N1/2009 influenza virus vaccine administered to adults during two randomized controlled trials. Clin Vaccine Immunol. 2011, 18: 835-843.
Article
CAS
PubMed
PubMed Central
Google Scholar
Della CG, Nicolay U, Lindert K, Leroux-Roels G, Clement F, Castellino F, Galli G, Groth N, Del Giudice G: Superior immunogenicity of seasonal influenza vaccines containing full dose of MF59® adjuvant: results from a dose-finding clinical trial in older adults. Hum Vaccin Immunother. 2012, 8: 216-227.
Article
Google Scholar
Vesikari T, Pepin S, Kusters I, Hoffenbach A, Denis M: Assessment of squalene adjuvanted and non-adjuvanted vaccines against pandemic H1N1 influenza in children 6 months to 17 years of age. Hum Vaccin Immunother. 2012, 8: 1283-1292.
Article
CAS
PubMed
PubMed Central
Google Scholar
Song JY, Cheong HJ, Noh JY, Seo YB, Choi WS, Cho GJ, Hwang TG, Kim WJ: Long-term and cross-reactive immunogenicity of inactivated trivalent influenza vaccine in the elderly: MF59-adjuvanted vaccine versus unadjuvanted vaccine. J Med Virol. 2013, 85: 1591-1597.
Article
CAS
PubMed
Google Scholar
Scheifele DW, McNeil SA, Ward BJ, Dionne M, Cooper C, Coleman B, Loeb M, Rubinstein E, McElhaney J, Hatchette T, Li Y, Montomoli E, Schneeberg A, Bettinger JA, Halperin SA, Research Network CI: Safety, immunogenicity, and tolerability of three influenza vaccines in older adults: results of a randomized, controlled comparison. Hum Vaccin Immunother. 2013, 9 (11): 2460-73.
Article
PubMed
PubMed Central
Google Scholar
Rümke HC, Richardus JH, Rombo L, Pauksens K, Plaßmann G, Durand C, Devaster JM, Dewé W, Oostvogels L: Selection of an adjuvant for seasonal influenza vaccine in elderly people: modelling immunogenicity from a randomized trial. BMC Infect Dis. 2013, 13: 348-
Article
PubMed
PubMed Central
Google Scholar
Garçon N, Vaughn DW, Didierlaurent AM: Development and evaluation of AS03, an adjuvant system containing α-tocopherol and squalene in an oil-in-water emulsion. Expert Rev Vaccines. 2012, 11: 349-366.
Article
PubMed
Google Scholar
Heijmans S, De Meulemeester M, Reynders P, Giet D, Demanet E, Devresse PY, Icardi G, Drame M, Roman F, Gillard P: Immunogenicity profile of a 3.75-μg hemagglutinin pandemic rH5N1 split virion AS03A-adjuvanted vaccine in elderly persons: a randomized trial. J Infect Dis. 2011, 203: 1054-1062.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ferguson M, Risi G, Davis M, Sheldon E, Baron M, Li P, Madariaga M, Fries L, Godeaux O, Vaughn D: Safety and long-term humoral immune response in adults after vaccination with an H1N1 2009 pandemic influenza vaccine with or without AS03 adjuvant. J Infect Dis. 2012, 205: 733-744.
Article
CAS
PubMed
Google Scholar
Morel S, Didierlaurent A, Bourguignon P, Delhaye S, Baras B, Jacob V, Planty C, Elouahabi A, Harvengt P, Carlsen H, Kielland A, Chomez P, Garçon N, Van Mechelen M: Adjuvant system AS03 containing alpha-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine. 2011, 29: 2461-2473.
Article
CAS
PubMed
Google Scholar
European Agency for the Evaluation of Medicinal Products: Committee for Proprietary Medicinal Products (CPMP): Note for Guidance on Harmonization of Requirements for Influenza Vaccines. CPMP/BWP/214/96, March 1997. [http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003945.pdf]
US Food and Drug Administration: Center for Biologics Evaluation and Research: Clinical Data Needed to Support the Licensure of Seasonal Inactivated Influenza Vaccines. May 2007. [http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm091990.pdf]
Murasko DM, Bernstein ED, Gardner EM, Gross P, Munk G, Dran S, Abrutyn E: Role of humoral and cell-mediated immunity in protection from influenza disease after immunization of healthy elderly. Exp Gerontol. 2002, 37: 427-439.
Article
CAS
PubMed
Google Scholar
McElhaney JE, Xie D, Hager WD, Barry MB, Wang Y, Kleppinger A, Ewen C, Kane KP, Bleackley RC: T cell responses are better correlates of vaccine protection in the elderly. J Immunol. 2006, 176: 6333-6339.
Article
CAS
PubMed
Google Scholar
Wilkinson TM, Li CK, Chui CS, Huang AK, Perkins M, Liebner JC, Lambkin-Williams R, Gilbert A, Oxford J, Nicholas B, Staples KJ, Dong T, Douek DC, McMichael AJ, Xu XN: Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med. 2012, 18: 274-280.
Article
CAS
PubMed
Google Scholar
Sridhar S, Begom S, Bermingham A, Hoschler K, Adamson W, Carman W, Bean T, Barclay W, Deeks JJ, Lalvani A: Cellular immune correlates of protection against symptomatic pandemic influenza. Nat Med. 2013, 19: 1305-1312.
Article
CAS
PubMed
Google Scholar
McElhaney JE, Beran J, Devaster JM, Esen M, Launay O, Leroux-Roels G, Ruiz-Palacios GM, van Essen GA, Caplanusi A, Claeys C, Durand C, Duval X, El IM, Falsey AR, Feldman G, Frey SE, Galtier F, Hwang SJ, Innis BL, Kovac M, Kremsner P, McNeil S, Nowakowski A, Richardus JH, Trofa A, Oostvogels L: AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial. Lancet Infect Dis. 2013, 13: 485-496.
Article
CAS
PubMed
Google Scholar
Moris P, van der Most R, Leroux-Roels I, Clement F, Dramé M, Hanon E, Leroux-Roels GG, Van Mechelen M: H5N1 influenza vaccine formulated with AS03A induces strong cross-reactive and polyfunctional CD4 T-cell responses. J Clin Immunol. 2011, 31: 443-454.
Article
CAS
PubMed
Google Scholar
Maecker HT, Maino VC, Picker LJ: Immunofluorescence analysis of T-cell responses in health and disease. J Clin Immunol. 2000, 20: 391-399.
Article
CAS
PubMed
Google Scholar
Waldrop SL, Davis KA, Maino VC, Picker LJ: Normal human CD4+ memory T cells display broad heterogeneity in their activation threshold for cytokine synthesis. J Immunol. 1998, 161: 5284-5295.
CAS
PubMed
Google Scholar
Boyman O: Bystander activation of CD4+ T cells. Eur J Immunol. 2010, 40: 936-939.
Article
CAS
PubMed
Google Scholar
Sfriso P, Ghirardello A, Botsios C, Tonon M, Zen M, Bassi N, Bassetto F, Doria A: Infections and autoimmunity: the multifaceted relationship. J Leukoc Biol. 2010, 87: 385-395.
Article
CAS
PubMed
Google Scholar
Hehme NW, Künzel W, Petschke F, Türk G, Raderecht C, van Hoecke C, Sänger R: Ten years of experience with the trivalent split-influenza vaccine, Fluarix™. Clin Drug Investig. 2002, 22: 751-769.
Article
CAS
Google Scholar
Hehme N, Engelmann H, Kuenzel W, Neumeier E, Saenger R: Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use. Virus Res. 2004, 103: 163-171.
Article
CAS
PubMed
Google Scholar
Reed LT, Muench H: A simple method of calculating fifty percent end point. Am J Hyg. 1938, 27: 493-498.
Google Scholar
Galli G, Medini D, Borgogni E, Zedda L, Bardelli M, Malzone C, Nuti S, Tavarini S, Sammicheli C, Hilbert AK, Brauer V, Banzhoff A, Rappuoli R, Del Giudice G, Castellino F: Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc Natl Acad Sci U S A. 2009, 106: 3877-3882.
Article
CAS
PubMed
PubMed Central
Google Scholar
Mbawuike I, Zang Y, Couch RB: Humoral and cell-mediated immune responses of humans to inactivated influenza vaccine with or without QS21 adjuvant. Vaccine. 2007, 25: 3263-3269.
Article
CAS
PubMed
PubMed Central
Google Scholar
McElhaney JE, Ewen C, Zhou X, Kane KP, Xie D, Hager WD, Barry MB, Kleppinger A, Wang Y, Bleackley RC: Granzyme B: correlates with protection and enhanced CTL response to influenza vaccination in older adults. Vaccine. 2009, 27: 2418-2425.
Article
CAS
PubMed
PubMed Central
Google Scholar
McKinstry KK, Strutt TM, Kuang Y, Brown DM, Sell S, Dutton RW, Swain SL: Memory CD4+ T cells protect against influenza through multiple synergizing mechanisms. J Clin Invest. 2012, 122: 2847-2856.
Article
CAS
PubMed
PubMed Central
Google Scholar
Co MD, Orphin L, Cruz J, Pazoles P, Rothman AL, Ennis FA, Terajima M: Discordance between antibody and T cell responses in recipients of trivalent inactivated influenza vaccine. Vaccine. 2008, 26: 1990-1998.
Article
CAS
PubMed
PubMed Central
Google Scholar
Mahnke YD, Saqr A, Hazenfeld S, Brady RC, Roederer M, Subbramanian RA: Age-related changes in durability and function of vaccine-elicited influenza-specific CD4(+) T-cell responses. Vaccine. 2011, 29: 8606-8614.
Article
CAS
PubMed
PubMed Central
Google Scholar
Hsu JP, Phoon MC, Koh GC, Chen MI, Lee VJ, Wu Y, Xie ML, Cheong A, Leo YS, Chow VT: Comparison of neutralizing antibody and cell-mediated immune responses to pandemic H1N1 2009 influenza virus before and after H1N1 2009 influenza vaccination of elderly subjects and healthcare workers. Int J Infect Dis. 2012, 16: e621-e627.
Article
CAS
PubMed
Google Scholar
Pedersen GK, Madhun AS, Breakwell L, Hoschler K, Sjursen H, Pathirana RD, Goudsmit J, Cox RJ: T-helper 1 cells elicited by H5N1 vaccination predict seroprotection. J Infect Dis. 2012, 206: 158-166.
Article
CAS
PubMed
Google Scholar
Bentebibel SE, Lopez S, Obermoser G, Schmitt N, Mueller C, Harrod C, Flano E, Mejias A, Albrecht RA, Blankenship D, Xu H, Pascual V, Banchereau J, Garcia-Sastre A, Palucka AK, Ramilo O, Ueno H: Induction of ICOS+CXCR3+CXCR5+ TH cells correlates with antibody responses to influenza vaccination. Sci Transl Med. 2013, 5: 176ra32-
Article
PubMed
PubMed Central
Google Scholar
Roman F, Vaman T, Kafeja F, Hanon E, Van Damme P: AS03A-Adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age. Clin Infect Dis. 2010, 51: 668-677.
Article
CAS
PubMed
Google Scholar
McElhaney JE: Influenza vaccine responses in older adults. Ageing Res Rev. 2011, 10: 379-388.
Article
CAS
PubMed
Google Scholar
Zhou X, McElhaney JE: Age-related changes in memory and effector T cells responding to influenza A/H3N2 and pandemic A/H1N1 strains in humans. Vaccine. 2011, 29: 2169-2177.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kelso A: CD4+ T cells limit the damage in influenza. Nat Med. 2012, 18: 200-202.
Article
CAS
PubMed
Google Scholar